The global colloids market size was valued at USD 3.61 billion in 2025 and is projected to grow from USD 3.80 billion in 2026 to USD 5.75 billion by 2034, registering a CAGR of 5.3% during the forecast period from 2026 to 2034. North America dominated the colloids market with a market share of 38.4% in 2025.
Colloids refer to substances dispersed evenly in another substance. In the context of blood plasma, colloids are primarily proteins such as albumin, globulins, and fibrinogen. These proteins contribute to the osmotic pressure of blood, helping to maintain fluid balance between blood vessels and tissues. Albumin, the most abundant plasma protein, assists in transporting hormones, fatty acids, and drugs, while globulins play a critical role in immune function by carrying antibodies.
Download a Free Sample To learn more about this report,
Adoption of Automated Plasma Collection and Processing
Advances in plasma collection technology are shifting the market toward automated systems that integrate plasma separation, donor monitoring, and collection into standardized workflows, reducing manual handling and improving processing consistency; the FDA cleared the NexSys PCS plasma collection system in February 2026 for automated collection of source plasma and plasma for transfusion.
Shift Toward Room-Temperature-Stable Plasma Products Drive Market
Cold-chain requirements and limited access to frozen-storage infrastructure are encouraging the development of room-temperature-stable plasma products, allowing plasma to be transported and used in settings where conventional freezers are difficult to maintain; in July 2026, the FDA licensed EZPLAZ as the first freeze-dried plasma product in the U.S., with room-temperature stability and rapid reconstitution for emergency and remote settings.
Increasing Prevalence of Immunodeficiency Disorders and Expansion of Hospital-Based Transfusion Services Drive Market
The increasing prevalence of immunodeficiency disorders is raising demand for plasma-derived immunoglobulins used in replacement therapy. Patients with primary or secondary antibody deficiencies require regular immunoglobulin treatment to maintain adequate immune protection and reduce recurrent infections. For example, intravenous immunoglobulin (IVIG) is used in patients with primary immunodeficiency to provide the antibodies their bodies cannot produce sufficiently. Higher treatment requirements increase demand for recovered plasma and encourage suppliers to maintain adequate fractionation and plasma-processing capacity. This sustained clinical need supports demand across the colloids (blood plasma) market.
The expansion of hospital-based transfusion services is increasing demand for plasma products used in bleeding management and surgical care. Higher volumes of trauma treatment, complex surgeries, and critical-care procedures require hospitals to maintain sufficient plasma inventories for patients with significant blood loss or coagulation deficiencies. For example, fresh frozen plasma is administered to patients with multiple coagulation-factor deficiencies when rapid replacement is required. Greater hospital utilization increases procurement requirements for plasma products and strengthens demand across healthcare supply chains. The expansion of transfusion services therefore supports continued market demand for blood plasma products.
Shortage of Plasma Donors and Risk of Plasma-Derived Product Contamination Restrain Market Expansion
An insufficient pool of regular plasma donors can restrict the volume of plasma available for collection and fractionation. Limited donor availability can create supply gaps and make it difficult for manufacturers and healthcare providers to maintain consistent inventories. These constraints can limit product availability and slow market expansion.
Potential contamination during plasma collection, processing, or handling requires extensive screening, pathogen testing, and quality-control measures. These safeguards increase processing complexity, operating costs, and compliance requirements for plasma-derived products. Higher safety and production burdens can affect product availability and limit adoption across transfusion and therapeutic applications.
Development of Albumin-Based Therapeutic Products and Growth of Plasma Fractionation Capacity Offer Growth Opportunities
Pharmaceutical companies and plasma-product manufacturers can target clinical applications for albumin in critical care, liver disorders, trauma, and severe burns. CSL Behring and Grifols offer albumin therapies, creating revenue through specialized formulations and hospital supply agreements. Additional albumin applications can expand product portfolios and improve the commercial value of processed plasma. Long-term hospital demand can also support recurring sales of albumin-based therapies.
Plasma processors can expand fractionation facilities to convert collected plasma into albumin, immunoglobulins, and other therapeutic proteins. Grifols has invested in additional fractionation and purification capacity, supporting higher processing volumes. Higher capacity can support larger product volumes and strengthen revenue from plasma-derived medicin
Regulatory Differences Across Markets and Complex Plasma Fractionation and Product Consistency Hinders Growth
Different requirements for plasma collection, donor eligibility, traceability, fractionation, and product approval increase the complexity of entering new geographic markets. For example, differences between U.S. and European plasma regulations can require manufacturers to maintain market-specific compliance processes, extending commercialization timelines and increasing operational complexity.
Converting plasma into albumin, immunoglobulins, and other therapeutic products requires tightly controlled fractionation and purification processes. For example, immunoglobulin manufacturing involves multiple processing and quality-control stages, making capacity expansion difficult when facilities lack specialized fractionation infrastructure.
The natural type colloids segment accounted for a share of 63.7% in 2025, owing to their established use in plasma volume expansion and fluid replacement applications. The synthetic type colloids segment provides an alternative for volume replacement and is used where manufactured colloid solutions are preferred.
The synthetic type colloids segment is expected to grow at a CAGR of 6.08% during the forecast period 2026-2034, supported by continued demand for plasma volume replacement and their availability across clinical settings.
Request Customizationto receive a tailored report.
The massive blood or plasma loss segment accounted for a share of 34.5% in 2025, owing to the need for rapid plasma volume restoration following substantial fluid loss. The hypovolemic shock segment supports volume resuscitation in patients experiencing severe circulatory volume depletion, while the extensive burns segment is associated with fluid replacement following major burn injuries. The others segment includes additional clinical situations requiring colloid-based volume expansion.
The hypovolemic shock segment is expected to grow at a CAGR of 7.18% during the forecast period 2026-2034, driven by the need for effective volume resuscitation in severe hypovolemia and shock management. The massive blood or plasma loss and extensive burns segments continue to support demand through their respective fluid replacement requirements, while the others segment serves additional applications.
Speak to an Analystto discuss market opportunities.
The North America colloids (blood plasma) market accounted for the largest regional share of 38.4% in 2025, supported by sustained demand for plasma-derived therapies, with the U.S. Department of Health and Human Services reporting that about 125,000 Americans rely on plasma-derived medicines for serious and rare diseases, while plasma-based therapies require hundreds to more than 1,200 donations per patient annually, depending on the condition.
The United States colloids (blood plasma) market is expected to benefit from an aging population, with the National Institute on Aging projecting the number of Americans aged 65 and older to reach 70.3 million by 2030, representing about 20% of the population, while the population aged 85 and older is projected to reach at least 19.4 million by 2050, supporting long-term demand for plasma-derived therapies and healthcare products.The Canada colloids (blood plasma) market is expected to benefit from population aging, with Statistics Canada projecting the share of people aged 65 and older to increase from 18.9% in 2023 to between 21.9% and 32.3% by 2073, while the population aged 85 and older is projected to rise from 896,600 in 2023 to 3.3–4.3 million by 2073, increasing the long-term need for healthcare and plasma-derived therapies.
Unlock Regional Insightsto access country-level data, & regional trends.
The Asia Pacific colloids (blood plasma) market is expected to grow at a CAGR of 8.12% during the forecast period 2026–2034, showcasing the fastest-growing regional market, supported by the WHO’s 2026–2030 Action Framework to expand access to safe blood and plasma-derived medicinal products, while demand for plasma-derived therapies continues to exceed supply in several countries across the region.The Japan colloids (blood plasma) market is expected to benefit from population aging, with Japan’s National Institute of Population and Social Security Research projecting the share of people aged 65 and above to increase from 28.6% in 2020 to 38.7% by 2070, while the total population is projected to decline from 126.15 million to 87 million, supporting sustained demand for plasma-derived healthcare products. The China colloids (blood plasma) market is expected to benefit from population aging, with China projecting the population aged 60 and above to increase from 300 million in 2025 to 417 million by 2035 and 487 million by 2050, raising its share of the population from 21.4% to 29.9% and 35.8%, respectively, supporting long-term demand for plasma-derived healthcare products.The South Korea colloids (blood plasma) market is expected to benefit from population aging, with Statistics Korea projecting the population aged 65 and above to increase from 8.98 million in 2022 to 17.27 million by 2072, raising its share from 17.4% to 47.7%, which is expected to increase long-term healthcare demand, including plasma-derived therapies. The India colloids (blood plasma) market is expected to benefit from population aging, with UNFPA projecting the population aged 60 and above to reach 346 million by 2050, representing nearly 21% of the total population, while the population aged 80 and above is projected to grow by around 279% between 2022 and 2050, supporting long-term demand for healthcare and plasma-derived products.
The Europe colloids (blood plasma) market accounted for a regional share of 27.6% in 2025, supported by continued demand for plasma-derived medicinal products, with the European Commission reporting that the EU collects around 8.4 million litres of plasma annually for medicine manufacturing and implementing new Substances of Human Origin rules from August 2027 to improve plasma supply, safety, cross-border exchange, and patient access.
The UK colloids (blood plasma) market is expected to benefit from population aging, with the Office for National Statistics projecting the number of people aged 85 and over to increase from 1.75 million in 2024 to 3.6 million by 2049, while their share of the population is projected to rise from 2.5% to 4.9%, supporting long-term demand for plasma-derived healthcare products. The Germany colloids (blood plasma) market is expected to benefit from population aging, with Germany’s Federal Statistical Office projecting one in four people to be aged 67 or older by 2035, while the number of people of pensionable age is expected to increase by at least 3.8 million by 2038, supporting demand for plasma-derived therapies and healthcare products.
The France colloids (blood plasma) market is expected to benefit from population aging, with INSEE projecting the number of people aged 65 and older to increase from 15.3 million in 2026 to 21.1 million by 2070, while the population aged 80 and older is projected to rise by 4.6 million to nearly 9 million, supporting long-term demand for plasma-derived healthcare products.
The colloids (blood plasma) market is moderately fragmented, with participation from plasma-derived product manufacturers, biopharmaceutical companies, blood and plasma collection organizations, specialty healthcare suppliers, and regional providers. The leading players in the global colloids (blood plasma) market are CSL Behring, Baxter, Grifols, S.A., Octapharma, and Shanghai RAAS Blood Products Co. Ltd., with the top three companies collectively accounting for approximately 46% of the global colloids (blood plasma) market share; a reliable cumulative share specifically for all five is not publicly disclosed.
Established players compete primarily on plasma collection capacity, product quality, manufacturing scale, regulatory compliance, supply reliability, clinical expertise, and established relationships with healthcare institutions. Emerging and regional players in the colloids (blood plasma) market ecosystem compete through specialized plasma-derived formulations, efficient collection and processing models, localized supply networks, improved purification technologies, and application-specific products.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Genome Editing Market Size, Share, Growth, Analysis, Report, 2034
Organ Preservation Market Size, Share, Growth, Analysis, Report, 2034
Bacteriophage Market Size, Share, Growth, Analysis, 2034
Epigenetics Market Size, Share, Growth, Analysis, Report, 2034
Biobanking Market Size, Share, Growth, 2034
Cell Therapy Manufacturing Market Size, Share, Growth, 2034
We are featured on:
sales@straitsresearch.com